Explanipedia

Algae extract supplementation boosts humoral immunity induced by attenuated PRRSV-1 vaccination Open

Caroline Hervet, Frédérick Bussy, Anne Morvan, Fabrizio Di Pinto, Catherine Belloc , et al. · 2025

Post-vaccination supplementation had no significant effect on vaccine viral load or humoral response, though a modest reduction in viral persistence was noted at 12 days post-vaccination (dpv). In contrast, pre-vaccination supplementation …

Induction of HIV-1-specific antibody-mediated effector functions by native-like envelope trimers in humans Open

Marloes Grobben, Emma I. M. M. Reiss, Angela I. Schriek, Karlijn van der Straten, Nathalie Dereuddre‐Bosquet , et al. · 2025

A protective vaccine is urgently needed to curb the ongoing global HIV-1 epidemic. There is increased interest to develop a vaccine able to induce both neutralizing antibodies and antibody-mediated effector functions for additional efficac…

Le modèle d’infection SARS-CoV-2 chez le primate non-humain, un outil préclinique pour la compréhension de la physiopathologie et l’évaluation de l’efficacité de candidats thérapeutiques et vaccinaux Open

Laëtitia Bossevot, Emma Burban, Ornella Dissake Attiapo, Nina Dhooge, Blanche Fert , et al. · 2025

L’émergence de maladies infectieuses présentant un risque pour la population humaine requiert des outils et modèles expérimentaux permettant de caractériser ces maladies afin de mieux s’en protéger. Suite à l’apparition du SARS-CoV-2, nous…

Comparative impact of porcine reproductive and respiratory virus and swine influenza A virus infections on respiratory lymph nodes B cells and macrophages Open

Caroline Hervet, Aline Perrin, Patricia Renson, Céline Deblanc, Marta Muñoz , et al. · 2024

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) strongly impacts the pig rearing sector due to its persistence in infected animals. Interestingly, although the PRRSV family exhibits considerable genome variability, with the PRR…

The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection Open

Déborah Lécuyer, Roberta Nardacci, Désirée Tannous, Emie Gutierrez-Mateyron, Aurélia Deva Nathan , et al. · 2023

Purinergic receptors and NOD-like receptor protein 3 (NLRP3) inflammasome regulate inflammation and viral infection, but their effects on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain poorly understood. Here…

Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates Open

Aurélien Marc, Romain Marlin, Flora Donati, Mélanie Prague, Marion Kerioui , et al. · 2023

The impact of variants of concern (VoC) on SARS-CoV-2 viral dynamics remains poorly understood and essentially relies on observational studies subject to various sorts of biases. In contrast, experimental models of infection constitute a p…

The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection Open

Déborah Lécuyer, Roberta Nardacci, Désirée Tannous, Emie Gutierrez-Mateyron, Aurélia Deva-Nathan , et al. · 2023

Purinergic receptors and NOD-like receptor protein 3 (NLRP3) inflammasome regulate inflammation and viral infection, but their effects on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain poorly understood. Here…

Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates Open

E. I. M. M. Reiss, Marlies M. van Haaren, Jelle van Schooten, Mathieu Claireaux, Pauline Maisonnasse , et al. · 2022

Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates Open

Aurélien Marc, Romain Marlin, Flora Donati, Mélanie Prague, Marion Kerioui , et al. · 2022

The impact of variants of concern (VoC) on SARS-CoV-2 viral dynamics remains poorly understood and essentially relies on observational studies subject to various sorts of biases. In contrast, experimental models of infection constitute a p…

Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques Open

Matthieu Van Tilbeurgh, Pauline Maisonnasse, Jean‐Louis Palgen, Monica Tolazzi, Yoann Aldon , et al. · 2022

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates Open

Romain Marlin, Delphine Desjardins, Vanessa Contreras, Guillaume Lingas, Caroline Solas , et al. · 2022

Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development Open

Julie Bigay, Roger Le Grand, Frédéric Martinon, Pauline Maisonnasse · 2022

The fight against infectious diseases calls for the development of safe and effective vaccines that generate long-lasting protective immunity. In a few situations, vaccine-mediated immune responses may have led to exacerbated pathology upo…

Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection Open

Marie Alexandre, Romain Marlin, Mélanie Prague, Séverin Coléon, Nidhal Kahlaoui , et al. · 2022

The definition of correlates of protection is critical for the development of next-generation SARS-CoV-2 vaccine platforms. Here, we propose a model-based approach for identifying mechanistic correlates of protection based on mathematical …

Detection of SARS-CoV-2 in subcutaneous fat but not visceral fat, and the disruption of fat lymphocyte homeostasis in both fat tissues in the macaque Open

Anaëlle Olivo, Romain Marlin, Thierry Lazure, Pauline Maisonnasse, Laëtitia Bossevot , et al. · 2022

The well documented association between obesity and the severity of SARS-CoV-2 infection raises the question of whether adipose tissue (AT) is impacted during this infection. Using a model of SARS-CoV-2 infection in cynomolgus macaques, we…

Author response: Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection Open

Marie Alexandre, Romain Marlin, Mélanie Prague, Séverin Coléon, Nidhal Kahlaoui , et al. · 2022

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques Open

Nerea Zabaleta, Urja Bhatt, Cécile Herate, Pauline Maisonnasse, Julio Sanmiguel , et al. · 2022

A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model Open

Claire-Maëlle Fovet, Camille Pimienta, Mathilde Galhaut, Francis Relouzat, Natalia Nunez , et al. · 2022

Most children are less severely affected by coronavirus-induced disease 2019 (COVID-19) than adults, and thus more difficult to study progressively. Here, we provide a neonatal nonhuman primate (NHP) deep analysis of early immune responses…

2nd EURO GEROSCIENCE Conference Posters Open

Aurora Román-Domínguez, Consuelo Borrás, Platform Álvaro Maciel, Eujessika Silva, Daniella Carvalho , et al. · 2022

Computed tomography and [18F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates Open

Thibaut Naninck, Nidhal Kahlaoui, Julien Lemaître, Pauline Maisonnasse, Antoine De Mori , et al. · 2022

SARS-COV-2 infection causes massive lung-cell senescence Open

E. Born, Pauline Maisonnasse, Charles Fouillade, Quentin Pascal, E. Marcos , et al. · 2022

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection Open

Guidenn Sulbarán, Pauline Maisonnasse, Axelle Amen, Grégory Effantin, Delphine Guilligay , et al. · 2022

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused an ongoing global health crisis. Here, we present as a vaccine candidate synthetic SARS-CoV-2 spike (S) glycoprotein-coated lipid vesicles that resemble v…

Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection Open

Pauline Maisonnasse, Thierry Poynard, Mehdi Sakka, Sepideh Akhavan, Romain Marlin , et al. · 2022

A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern Open

Mitch Brinkkemper, Philip J. M. Brouwer, Pauline Maisonnasse, Marloes Grobben, Tom G. Caniels , et al. · 2021

The emergence of SARS-CoV-2 variants that are more resistant to antibody-mediated neutralization pose a new hurdle in combating the COVID-19 pandemic. Although vaccines based on the original Wuhan sequence have been shown to be effective a…

SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines Open

Marie Alexandre, Romain Marlin, Mélanie Prague, Séverin Coléon, Nidhal Kahlaoui , et al. · 2021

The definition of correlates of protection is critical for the development of next generation SARS-CoV-2 vaccine platforms. Here, we propose a new framework for identifying mechanistic correlates of protection based on mathematical modelli…

Hydroxychloroquine against COVID-19? Let’s listen to monkeys! Open

Pauline Maisonnasse, Roger Le Grand · 2021

Since the beginning of the COVID-19 pandemic, many drugs have been tested to improve patient outcomes or reduce transmission. One of these drugs has generated hopes and tensions around the globe: hydroxychloroquine. We studied its effect a…

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models Open

Pauline Maisonnasse, Yoann Aldon, Aurélien Marc, Romain Marlin, Nathalie Dereuddre‐Bosquet , et al. · 2021

Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effec…

Author response: Cross-reactive antibodies after SARS-CoV-2 infection and vaccination Open

Marloes Grobben, Karlijn van der Straten, Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse , et al. · 2021

Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronav…

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques Open

Romain Marlin, Véronique Godot, Sylvain Cardinaud, Mathilde Galhaut, Séverin Coléon , et al. · 2021

An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates Open

Nerea Zabaleta, Wenlong Dai, Urja Bhatt, Cécile Herate, Pauline Maisonnasse , et al. · 2021

The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses …

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection Open

Guidenn Sulbarán, Pauline Maisonnasse, Axelle Amen, Delphine Guilligay, Nathalie Dereuddre‐Bosquet , et al. · 2021

The SARS-CoV-2 pandemic causes an ongoing global health crisis, which requires efficient and safe vaccination programs. Here, we present synthetic SARS-CoV2 S glycoprotein-coated liposomes that resemble in size and surface structure virus-…

Pauline Maisonnasse YOU? Author Swipe